PGRP作为小细胞肺癌肿瘤标志物的临床价值与检测方法
The Clinical Application and Detection Methods of Small Cell Lung Cancer Tumor Marker: Pro-Gastrin Releasing Peptide

作者: 楚振宇 , 周小林 :中国辐射防护研究院,太原;

关键词: 前胃泌素释放肽肿瘤标志物小细胞肺癌Pro-Gastrin Releasing Peptide Tumor Marker Small Cell Lung Cancer

摘要:

前胃泌素释放肽(pro-gastrin releasing peptide, PGRP)是一种新型小细胞肺癌(SCLC)肿瘤标志物。大量研究证明其在诊断与鉴别诊断SCLC方面较其他肿瘤标志物有更良好的表现,在早期筛查、治疗监测、预后评价、复发预测等方面也有一定价值,与其他标志物联合检测可以进一步提高诊断准确性。本文对PGRP作为SCLC肿瘤标志物的临床应用价值及检测方法做一综述,探讨进一步研究方向,以期对临床诊断和治疗提供技术支持。

Abstract:
Progastrin releasing peptide (PGRP) is a new type of small cell lung cancer (SCLC) tumor markers. Numerous studies have demonstrated its better performance compared with other tumor markers in the diagnosis of SCLC, and considerable value in early screening, treatment evaluating, prognosis prediction and progression monitoring. Moreover, combined use of PGRP with other tumor markers may possess higher diagnostic accuracy than any alone does. Here we review the new progresses in the clinical application of PGRP as the SCLC tumor marker, and discuss the future directions.

文章引用: 楚振宇 , 周小林 (2014) PGRP作为小细胞肺癌肿瘤标志物的临床价值与检测方法。 世界肿瘤研究, 4, 11-17. doi: 10.12677/WJCR.2014.42003

参考文献

[1] 钱桂生, 余时沧 (2012) 肺癌流行病学最新资料与启示. 中华结核和呼吸杂志, 35, 86-89.

[2] McDonald, T.J., Nilsson, G., Vagne, M., et al. (1978) A gastrin releasing peptide from the porcine non-antral gastric tissue. Gut, 19, 767-764.

[3] Cuttitta, F., Carney, D.N., Mulshine, J., et al. (1985) Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature, 316, 823-826.

[4] Yamaguchi, K., Abe, K., Kameya, T., et al. (1983) Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Research, 43, 3932-3939.

[5] Maruno, K., Yamaguchi, K., Abe, K., et al. (1989) Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Research, 49, 629-632.

[6] Miyake, Y., Kodama, T. and Yamaguchi, K. (1994) Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Research, 54, 2136-2140.

[7] Torsetnes, S.B., Nordlund, M.S., Paus, E., et al. (2013) Digging deeper into the field of the small cell lung cancer tumor marker PGRP: A method for differentiation of its isoforms. Journal of Proteomic Research, 12, 412-420.

[8] Thomas, L. (1998) Clinical laboratory diagnostics: Use and assessment of clinical laboratory results. Verlagsgesellschaft mbH, Germany.

[9] Slodkowska, J., Zych, J., Szturmowicz, M., et al. (2005) Neuroendocrine phenotype of non-small cell lung carcinoma: Immunohistological evaluation and biochemical study. The International Journal of Biological Markers, 20, 217-226.

[10] Shibayama, T., Ueoka, H., Nishii, K., et al. (2001) Complementary roles of pro-gastrin-releasing peptide (PGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer. Lung Cancer, 32, 61-69.

[11] 杨谨, 李蓉, 李昂, 等 (2000) 前胃泌素释放肽片段31-98检测对小细胞肺癌的临床意义. 中华肿瘤杂志, 22, 216-218.

[12] Nisman, B., Biran, H., Ramu, N., et al. (2009) The diagnostic and prognostic value of PGRP in lung cancer. Anticancer Research, 29, 4827-4832.

[13] 赵先文, 荆洁线, 韩存芝, 等 (2011) 小细胞肺癌血清PGRP(31-98)与神经元性烯醇化酶同步检测的临床价值及其想关性. 肿瘤研究与临床, 23, 518-521.

[14] 金霞霞, 陈世勇, 齐娟飞, 等 (2012) 血清NSE、PGRP、CEA、SCCA和CYFRA21-1联检在肺癌诊断中的意义. 放射免疫学杂志, 25, 83-86.

[15] Yang, H.J., Gu, Y., Chen, C., et al. (2011) Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: A meta-analysis. Clinical Chemistry and Laboratory Medicine, 49, 1039-1046.

[16] Tang, J.H., Zhang, X.L., Zhang, Z.H., et al. (2011) Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: A systematic review. Chinese Medical Journal, 124, 1563-1568.

[17] 周明非, 张贺秋, 凌世淦 (2000) 小细胞肺癌肿瘤标志物——前胃泌素释放肽酶联免疫检测方法的研究进展. 军事医学科学院院刊, 24, 143-146.

[18] 蒋安帮, 黄礼年 (2012) 前胃泌素释放肽在肺癌中的临床意义. 医学综述, 18, 200-202.

[19] Kudo, K., Ohyanagi, F., Horiike, A., et al. (2011) Clinicopathological finding of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations. Lung Cancer, 74, 401-404.

[20] Korse, C.M., Taal, B.G., Vincent, A., et al. (2012) Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments. European Journal of Cancer, 48, 662-671.

[21] Molina, R., Auge, J.M., Alicarte, J., et al. (2004) Progastrin-releasing peptide in patients with benign and malignant disease. Tumor Biology, 25, 56-61.

[22] Ando, S., Kimura, H., Iwai, N., et al. (2001) Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Research, 21, 3085-3092.

[23] 王敏杰, 李学祥, 高佳, 等 (2011) 血清PGRP、TPS及NSE在小细胞肺癌患者治疗监测中的应用. Chinese Journal of Laboratory Medicine, 34, 152-157.

[24] 金欣, 陈健魁, 佟雅丽, 等 (2007) 血清PGRP、NSE、CYFRA21-1联合检测对肺癌诊断和治疗的临床意义. 中国卫生检验杂志, 17, 1008-1022.

[25] Stieber, P. (2009) Pro-gastrin-releasing peptide (PGRP)—A diagnostic biomarker for small-cell lung cancer. Chinese Journal of Lung Cancer, 12, 183-186.

[26] Wójcik, E., Kulpa, J.K., Sas-Korczyńska, B., et al. (2008) PGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Research, 28, 3027-3033.

[27] Holdenrieder, S., von Pawel, J., Dankelmann, E., et al. (2008) Nucleosomes, PGRP, NSE, CYFRA21-1 and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clinical Cancer Research, 14, 7813-7821.

[28] Niho, S., Nishiwaki, Y., Goto, K., et al. (2000) Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: Comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer, 27, 159-167.

[29] Shibayama, T., Ueoka, H., Nishii, K., et al. (2001) Complementary roles of pro-gastrin-releasing peptide (PGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 32, 61-69.

[30] Ono, A., Naito, T., Ito, I., et al. (2012) Correlationgs between seria pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. Lung Cancer, 76, 439-444.

[31] Okusaka, T., Eguchi, K., Kasai, T., et al. (1997) Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clinical Cancer Research, 3, 123-127.

[32] Hirose, T., Okuda, K., Yamaoka, T., et al. (2011) Are levels of pro-gastrin-releasing peptide or nerron-specific enolase at relapse prognostic factors after reapse in patients with small-cell lung cancer. Lung Cancer, 71, 224-228.

[33] Sunaga, N., Tsuchiya, S., Minato, K., et al. (1999) Serumpro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology, 57, 143-148.

[34] Kim, H.-R., Oh, I.-J., Shin, M.-G., et al. (2011) Plasma PGRP concentratiois sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer. Journal of Korean Medical Science, 26, 625-630.

[35] Nordlund, M.S., Bjerner, J., Warren, D.J., et al. (2008) Progastrin-releasing peptide: Stability in plasma/serum and upper reference limit. Tumor Biology, 29, 204-210.

[36] Yoshimura, T., Fujita, K., Kawakami, S., et al. (2008) Stability of pro-gastrin-releasing peptide in serum versus plasma. Tumor Biology, 29, 224-230.

[37] Nordlund, M.S., Stieber, P., Brustugun, O.T., et al. (2012) Characteristics and clinical validity of two immunoassays for PGRP. Tumor Biology, 33, 1105-1113.

[38] Nordlund, M.S., Warren, D.J., Nustad, K., et al. (2008) Automated time-resolved immunofluorometric assay for progastrin-releasing peptide. Clinical Chemistry, 54, 919-922.

[39] Winther, B. and Reubsaet, J.L. (2007) Determination of the small cell lung cancer associated biomarker pro-gastrin-releasing peptide (PGRP) using LC-MS. Journal of Separation Science, 30, 234-240.

[40] Winther, B., Moi, P., Nordlund, M.S., et al. (2009) Absolute PGRP quantification in a clinical relevant concentration range using LC-MS/MS and a comprehensive internal standard. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 877, 1359-1365.

[41] Winther, B., Nordlund, M., Paus, E., et al. (2009) Immuno-capture as ultimate sample cleanup in LC-MS/MS determination of the early stage biomarker PGRP. Journal of Separation Science, 32, 2937-2943.

[42] 石怡珍, 周小林, 徐巧玲, 等 (2010) 碘131-抗PGRP(31-98)单克隆抗体E-B5放射免疫显像及放射免疫治疗实验研究. 中华核医学杂志, 30, 110-115.

[43] 陈传新, 石怡珍, 杨仪, 等 (2011) 抗PGRP(31-98)单克隆抗体D-D3的碘-131标记及其体内生物学分布研究. 重庆医学, 40, 752-754.

[44] 徐巧玲, 周小林, 石怡珍, 等 (2009) 抗PGRP(31-98)单克隆抗体E-B5的碘-131标记及体内生物分布研究. 中华核医学杂志, 29, 274-278.

[45] 周小林, 蘧艳峰, 薛振伟, 等 (2010) 小细胞肺癌PGRP基因的克隆及疫苗构建. 免疫学杂志, 26, 651-655.
http://www.cajcd.edu.cn/pub/wml.html

分享
Top